{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Patient&page=62",
    "query": {
      "condition": "Cancer Patient",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 26239,
    "total_pages": 2624,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Patient&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Patient&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T02:20:02.182Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01307891",
      "title": "Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer",
        "Stage IV Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abraxane alone",
          "type": "DRUG"
        },
        {
          "name": "Abraxane + Tigatuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2011-03",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307891"
    },
    {
      "nct_id": "NCT00278174",
      "title": "Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alpha-1b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2005-02",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2011-05-04",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00278174"
    },
    {
      "nct_id": "NCT00659984",
      "title": "N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "UltratraceTM Iobenguane I 131 Imaging",
          "type": "DRUG"
        },
        {
          "name": "UltratraceTM Iobenguane I 131 Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Insight Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 15,
      "start_date": "2008-06",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2017-10-04",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00659984"
    },
    {
      "nct_id": "NCT01217333",
      "title": "Telephone-Based Decision Support for Rural Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "In-person CP",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Tele-CP",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 74,
      "start_date": "2007-10",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-10-18",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 2,
      "location_summary": "Mendocino, California • Ukiah, California",
      "locations": [
        {
          "city": "Mendocino",
          "state": "California"
        },
        {
          "city": "Ukiah",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217333"
    },
    {
      "nct_id": "NCT02574533",
      "title": "Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma Recurrent",
        "Malignant Melanoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-10",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-09-27",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 3,
      "location_summary": "Abilene, Texas • Dallas, Texas • Spokane, Washington",
      "locations": [
        {
          "city": "Abilene",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574533"
    },
    {
      "nct_id": "NCT00014547",
      "title": "BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BBR 3464",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theradex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-07-24",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 18,
      "location_summary": "Hoover, Alabama • Fayetteville, Arkansas • Berkeley, California + 15 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Southington",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014547"
    },
    {
      "nct_id": "NCT04441138",
      "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-25",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04441138"
    },
    {
      "nct_id": "NCT01974258",
      "title": "Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Onartuzumab",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-02",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01974258"
    },
    {
      "nct_id": "NCT01725048",
      "title": "Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Mirtazapine",
          "type": "DRUG"
        },
        {
          "name": "Citalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-01",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2017-03-13",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01725048"
    },
    {
      "nct_id": "NCT02337426",
      "title": "Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Brain Glioblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Dimethyl Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-02-13",
      "completion_date": "2017-11-09",
      "has_results": false,
      "last_update_posted_date": "2019-06-28",
      "last_synced_at": "2026-10-28T02:20:02.182Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02337426"
    }
  ]
}